Feng Chen-Lin, Han Yan-Xing, Guo Hui-Hui, Ma Xiao-Lei, Wang Zhi-Qiang, Wang Lu-Lu, Zheng Wen-Sheng, Jiang Jian-Dong
a State Key Laboratory of Bioactive Substance and Function of Natural Medicines , Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , PR China.
Drug Deliv. 2017 Nov;24(1):1537-1548. doi: 10.1080/10717544.2017.1386732.
Our previous work proved that sequence specific double strand RNA (dsRNA-p21) effectively activated p21 gene expression of colorectal cancer (CRC) cells and consequently suppressed CRC growth. However, efficient delivery system is a significant challenge to achieve sufficient therapy. In this study, a self-assembled HA/PEI/dsRNA-p21 ternary complex (TC-dsRNA-p21) was developed for the tumor-target delivery of dsRNA-p21 into CRC cells. Hyaluronic acid (HA) was introduced to shield the PEI/dsRNA-p21 binary complexes (BC-dsRNA-p21) for reducing the cytotoxicity of PEI and for increasing the tumor-targeted intracellular uptake by cancer cells through HA-CD44 mediated endocytosis. Comparing to the BC-dsRNA-p21, the TC-dsRNA-p21 showed increase in size, decrease in zeta potential, low cytotoxicity as well as high stability in physiological conditions due to the anionic shielding. Confocal microscopy analysis and flow cytometry confirmed that TC-dsRNA-p21 had high transfection efficiency in the CD44-abundant Lovo cells, as compared with binary complex. In vitro physiological experiment showed that, comparing to the control group, the TC-dsRNA-p21 effectively activated the expression of p21 mRNA and P21 protein, causing blockage of cell cycle at G/G phase and suppression of cancer cell proliferation as well as colony formation. Furthermore, in vivo distribution experiment demonstrated that the TC-dsRNA-p21 could effectively accumulate at rectal wall for up to 10 h, following in situ application. These findings indicated that TC-dsRNA-p21 might hold great potential for delivering dsRNA-p21 to treat CRC.
我们之前的研究证明,序列特异性双链RNA(dsRNA-p21)可有效激活结肠直肠癌(CRC)细胞中p21基因的表达,从而抑制CRC的生长。然而,高效的递送系统是实现充分治疗的一项重大挑战。在本研究中,我们开发了一种自组装的HA/PEI/dsRNA-p21三元复合物(TC-dsRNA-p21),用于将dsRNA-p21肿瘤靶向递送至CRC细胞。引入透明质酸(HA)以屏蔽PEI/dsRNA-p21二元复合物(BC-dsRNA-p21),以降低PEI的细胞毒性,并通过HA-CD44介导的内吞作用增加癌细胞对肿瘤靶向的细胞内摄取。与BC-dsRNA-p21相比,由于阴离子屏蔽作用,TC-dsRNA-p21的尺寸增大、zeta电位降低、细胞毒性低且在生理条件下具有高稳定性。共聚焦显微镜分析和流式细胞术证实,与二元复合物相比,TC-dsRNA-p21在CD44丰富的Lovo细胞中具有高转染效率。体外生理学实验表明,与对照组相比,TC-dsRNA-p21有效激活了p21 mRNA和P21蛋白的表达,导致细胞周期在G/G期阻滞,并抑制癌细胞增殖以及集落形成。此外,体内分布实验表明,原位应用后,TC-dsRNA-p21可在直肠壁有效蓄积长达10小时。这些发现表明,TC-dsRNA-p21在递送dsRNA-p21治疗CRC方面可能具有巨大潜力。